Mesothelin promotes invasion and metastasis in breast cancer cells

Journal of International Medical Research

Volumn 40, Issue 6, 2012, Pages 2109-2116

  Wang, Y ^a   Wang, L ^a   Li, D ^a   Wang, H B ^a   Chen, Q F ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Angiogenesis; Breast cancer; Extracellular signal regulated kinase (ERK1 2); Matrix metalloproteinase 9 (MMP 9); Mesothelin; Metastasis; MSLN

Indexed keywords

GELATINASE B; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MSLN GENE; NONHUMAN; PERITONEUM METASTASIS; TUMOR GENE; UPREGULATION;

EID: 84872242356     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000608     Document Type: Article

References (22)

1. Hassan R, Bera T, Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10: 3937-3942.
2. Chang K, Pai LH, Batra JK, et al: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992; 52: 181-186.
3. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-3868.
4. Ho M, Bera TK, Willingham MC, et al: Mesothelin expression in human lung cancer. Clin Cancer Res 2007; 13: 1571-1575.
5. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-140.
6. Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418-1428.
7. Chang K, Pastan I, Willingham M: Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 1992; 51: 548-554.
8. Dainty LA, Risinger JI, Morrison C, et al: Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 2007; 105: 563-570.
9. Hassan R, Bullock S, Premkumar A, et al: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13: 5144-5149.
10. Hassan R, Schweizer C, Lu KF, et al: Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer 2010; 68: 455-459.
11. Le DT, Brockstedt DG, Nir-Paz R, et al: A liveattenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012; 18: 858-868.
12. Bera T, Pastan I: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902-2906.
13. Wang K, Bodempudi V, Liu Z, et al: Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One 2012; 7: e33214.
14. Chang MC, Chen CA, Chen PJ, et al: Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J 2012; 442: 293-302.
15. Servais EL, Colovos C, Rodriguez L, et al: Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012; 18: 2478-2489.
16. Wang L, Niu Z, Zhang L, et al: Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res 2012; 40: 909-916.
17. Li J, Jia L, Zhao P, et al: Stable knockdown of clusterin by vector-based RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res 2012; 40: 545-555.
18. Lu Z, Xu S: ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006; 58: 621-631.
19. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
20. Hayasaka A, Suzuki N, Fujimoto N, et al: Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996; 24: 1058-1062.
21. Lu Z, Lu N, Li C, et al: Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 2012; 209: 211-220.
22. Karroum A, Mirshahi P, Benabbou N, et al: Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways. Cancer Lett 2010; 295: 242-251.